Bulevirtide HDV Therapy: Promising Results in Durable Virologic Control

By João L. Carapinha

May 12, 2025

Bulevirtide HDV therapy has shown remarkable promise in Gilead’s final results from the Phase 3 MYR301 study. The findings indicate that longer bulevirtide monotherapy for chronic hepatitis delta virus (HDV) leads to sustained virologic suppression after stopping treatment. Notably, 36% of adults who achieved undetectable HDV RNA at the end of treatment maintained this suppression for nearly two years post-therapy. Furthermore, among those undetectable for at least 96 weeks during treatment, a striking 90% continued to show undetectability after therapy cessation, with no late relapses. These findings highlight bulevirtide’s potential for durable off-treatment virologic control in chronic HDV patients.

Key Insights on Bulevirtide’s Effectiveness

  • Durable Virologic Response: The MYR301 data show that patients achieving sustained undetectability of HDV RNA during treatment can maintain this response after therapy cessation, especially those undetectable for ≥96 weeks.
  • No Late Relapses Observed: No relapses were recorded during the second year of follow-up among patients who sustained undetectability for a year post-treatment.
  • Monotherapy Efficacy: Bulevirtide, as a standalone therapy, has shown significant efficacy and tolerability, alongside normalization of liver inflammation markers.
  • Novelty with HBV Co-infection: Achieving sustained HDV RNA undetectability while HBV surface antigen remains present is a clinical breakthrough.

The Urgent Need for Effective HDV Treatments

Chronic HDV is the most severe form of viral hepatitis, linked to rapid progression to liver cancer and mortality. Coinfection with HBV affects ~12 million globally. Effective therapies for chronic HDV have been lacking. Bulevirtide’s approval in the EU, UK, and Australia marks a breakthrough. Bulevirtide has received breakthrough designation in the US, with a biologics license application set for FDA review in 2025.

Health Economics and Outcomes Considerations

Bulevirtide’s durable response may improve cost-effectiveness by reducing long-term complications and hospitalizations. Payers may advocate for shorter treatment durations if durable off-treatment control is demonstrated. The findings suggest improved quality of life and slowed disease progression. Bulevirtide’s high sustained response rate sets a new benchmark for HDV therapy.

Conclusion: A Paradigm Shift in HDV Management

The MYR301 results show bulevirtide provides durable treatment for chronic HDV patients, especially those maintaining undetectable HDV RNA long-term. This marks a turning point in HDV management, with implications for patient outcomes and market access. Ongoing analysis will refine patient selection and optimize treatment duration. For more details, refer here.

Reference url

Recent Posts

Zimislecel type 1 diabetes
   

Cell Therapy for Type 1 Diabetes: Vertex Trial Results and Market Potential

🚀 What if we could revolutionize Type 1 diabetes treatment?

Vertex Pharmaceuticals has made significant strides with its promising phase 1/2 trial results for **zimislecel**, a stem cell-derived therapy that not only restores insulin production but also drastically reduces severe hypoglycemic events. As phase 3 trials commence, this breakthrough could reshape care for T1D patients and potentially reduce long-term healthcare costs.

Curious to learn how zimislecel and other potential cell therapies may redefine diabetes management? Click to read more!

#SyenzaNews #biotechnology #HealthEconomics

biosimilar clinical approach
    

Biosimilar Clinical Approach

🚀 How is the EMA’s new biosimilar clinical approach changing the landscape of drug approvals in Europe?

With a focus on tailored clinical assessments, the EMA is streamlining the pathway for biosimilars by allowing analytical data to take precedence over large-scale comparative efficacy studies. This shift promises to enhance patient access to life-saving therapies while maintaining rigorous safety standards.

Dive deeper into the implications of this innovative regulatory approach and find out how it can impact health economics and market access.

👉 Read more in the full article!
#SyenzaNews #regulatoryaffairs #MarketAccess

HIV prevention injection
   

FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Prevention

🌍 Will Yeztugo Approval and Access Strategy Deliver an Inflection Point in HIV/AIDS?

Yeztugo (lenacapavir), a twice-yearly injection, redefines long-acting HIV prevention with 96–100% efficacy. Gilead’s access strategy—insurance, assistance, and generics for 120 countries—targets global impact. Can it balance $28,218 U.S. costs with equity for 1.3M annual infections? My article explores health economics, public health, and market dynamics.

📖 Read how Yeztugo’s access strategy could transform long-acting HIV prevention

#SyenzaNews #GlobalHealth #HIVPrevention #Yeztugo #PrEP

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.